# Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

> **NCT00494767** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 27 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Obesity

## Interventions

- **DRUG:** GW869682
- **DRUG:** GSK189075
- **DRUG:** GSK189075-Placebo
- **DRUG:** GW869682-Placebo

## Key facts

- **NCT ID:** NCT00494767
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-29
- **Primary completion:** 2007-06-07
- **Final completion:** 2007-06-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494767, "Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00494767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*